The yield on the benchmark 10-year Treasury note fell below 2% for the first time since November 2016 on Wednesday — breaching a key psychological level.Bondsread more
The Fed came very close to promising a rate cut Wednesday, and now markets are focused on a possible July rate cut.Market Insiderread more
Markets had expected the central bank to keep its benchmark interest rate steady while setting up a cut at the July meeting.The Fedread more
Powell said policymakers are concerned about some of the recent economic developments and see a growing case for easier policy.The Fedread more
Amazon and Blue Origin founder Jeff Bezos gave more insight into his space company's lunar plans on Wednesday.Technologyread more
As the presidents of U.S. and China near a highly anticipated meeting on trade, the gap in both sides' expectations regarding a deal remains wide.World Politicsread more
Delta warned travelers that a technical problem could delay flights on Wednesday.Airlinesread more
The Fed chief said that despite reports that Trump was looking to demote or fire him, he doesn't plan on leaving anytime soon.The Fedread more
If the Trump administration and Congress fail to reach a spending agreement, the White House will offer to keep the government funded at its current levels for a year, Mnuchin...Politicsread more
With bold and targeted steps, economists say, government can increase opportunity and incomes for many more people in ways that strengthen, not weaken, American capitalism.Politicsread more
Investors need to be cautious because the economy will get hurt the longer the trade war drags on, Jim Cramer says.Mad Money with Jim Cramerread more
The CEO of the drug company founded by Martin Shkreli on Thursday called Shkreli a "Pied Piper" who entranced investors and co-workers with his bold predictions of pharmaceutical success.
Retrophin CEO Stephen Aselage, during testimony at Shkreli's securities fraud trial, also called him a "brilliant intellect" and a "visionary."
Shkreli was a "Pied Piper ... he tells a story, sings a song," Aselage said.
But there were times, Aselage testified, when Shkreli was "not as credible as he could have been."
And when questioned by a prosecutor about why he remained at Retrophin after being kept in the dark about some things Shkreli was doing, Aselage said, "Yeah, I've asked myself that question a number of times."
Shkreli, 34, is charged in Brooklyn, New York, federal court with looting Retrophin of stock shares and cash to pay off investors in two hedge funds he ran, whom he is also accused of defrauding.
He has denied the charges, which are unrelated to his controversial hiking of the price of a drug more than 5,000 percent in 2015 while leading another company, Turing Pharmaceuticals.
Shkreli founded Retrophin in 2011, shortly after witnesses have said his hedge fund MSMB Capital effectively imploded by making a disastrous short-sale trade of stock in another drug company.
Witnesses have also said that when they tried to withdraw their investments in Shkreli's hedge funds after he said they were closing operations, he put them off for up to a year or more.
And, they testified, instead of giving them just cash, as requested, he gave them stock in Retrophin in addition to cash and had them sign settlement agreements promising not to sue Shkreli or Retrophin.
Prosecutors claim that Shkreli also created sham consulting agreements with some investors, who ended up being paid by Retrophin, to cover the money that he had lost in his hedge funds.
Bank records indicate that money investors had sent to Shkreli's MSMB hedge funds sometimes was sent directly into Retrophin accounts, without their knowledge.
Aselage testified Thursday that while he was serving on Retrophin's board there were no discussions about settlement agreements that Shkreli had signed with MSMB fund investors, nor did the board ever approve such deals.
He also said the board never approved consulting agreements used to pay MSMB investors in Retrophin stock.
Aselage testified that Shkreli contacted him "out of the blue" in 2012 and said he wanted Aselage to join his new company, Retrophin.
In a later call, Aselage said, Shkreli talked about his vision for "a great, new pharmaceutical company" and claimed that he was a "very successful investment manager."
However, prosecutors have claimed, Shkreli had already failed at running one hedge fund, Elea Capital, and had lost much if not all of the investor money he was handling at the MSMB funds.
Aselage said he agreed to join Retrophin as CEO. During his tenure in that post, he testified, he found Shkreli to be "bright" and capable of "knocking down walls."
But Aselage also came to feel Shkreli was really the one in charge of the company, while using Aselage as the face of the firm.
Aselage said that shortly after starting his job he found out the Retrophin did not have funding for operations, contrary to what Shkreli had told him.
At one point, Aselage said, Retrophin was "running on fumes."
He also testified that there was a concern about commingling of finances between the MSMB funds and Retrophin, and that it sometimes wasn't clear which employees were working for which firm.
Aselage later found out that Retrophin did not have insurance for its directors and officers to protect them personally if they were sued in connection with company activities.
"It's America," Aselage said. "In America, you can sue everybody ... it can wipe out someone's life savings."
Aselage said the lack of insurance, and the questions about who was actually in charge of Retrophin, left him in an "untenable position."
He testified that he wanted to resign as both CEO and a member of the company's board of directors.
But Shkreli and another Retrophin official convinced him to remain on the board.
On Wednesday, the former chairman of the board of Retrophin, Steven Richardson, testified about the events that led the board to fire Shkreli in 2014 and to re-install Aselage as CEO.
Richardson said that instead of curbing stock trading by Retrophin employees in what was an effective hedge fund within the company, Shkreli set up a commission-incentive structure for those workers, and then lied about it to Richardson.
Richardson also testified that Shkreli had himself been trading in Retrophin stock during periods when he was barred from doing so, and also was giving some new employees company shares without keeping track of the amounts. That latter practice risked diluting the value of shares held by existing Retrophin investors.
Richardson, who is gay and who was an investor in Shkreli's fund, said he believed Shkreli was saying such things because he believed Richardson wanted to hear them.